Bibliography
- FIJEN JW, ZIJLSTRA JG, DE BOER P et al.: Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immune](2001) 124(1):16–20.
- •This article describes the clinical proof of principle studies that show the efficacy of a p38 MAP kinase inhibitor in humans.
- BRANGER J, VAN DEN BLINK B, S et al.: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. brimuna (2002) 168(8)4070–4077.
- •This article describes the clinical proof of principle studies that show the efficacy of BIRB796, a p38 MAP kinase inhibitor, in humans.
- MELDRUM DR: Tumor necrosis factor in heart. Ain. J. Physic]. (1998) 274(3):R577–R595.
- GAO FT, YUE TL, SHI DW et al.: p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardievasc. Res. (2002) 53(2):414–422.
- MOCANU MM, BAXTER GE YUE Y, CRITZ S, YELLON D: The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res.Cairliol. (2000) 95:472–478.
- NAKANO A, COHEN MV, CRITZ S, DOWNEY JM: SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res.Cairliol. (2000) 95(6):466–471.
- BADGER AM, BRADBEER JN, VOTTA B, LEE JC, ADAMS JL, GRISWOLD DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharinacol Exp.Thec (1996) 279(3):1453–1461.
- SANO I, TAKAHASHI T, KOJI T, UDONO H, YUI K, AYABE H: Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor. Heart Lung Transplant (2001) 20(5):583–589.
- JARRAR D, WANG P, SONG GY, CIOFFI WG, BLAND KI, CHAUDRY I: Inhibition of tyrosine kinase signaling after trauma-hemorrhage: a novel approach for improving organ function and decreasing susceptibility to subsequent sepsis. Ann. Suig. (2000) 231(3):399–407.
- DUNN SL, YOUNG EA, HALL MD, MCNULTY S: Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia (2002) 37(1):31–42.
- ZHU J, ROTTKAMP CA, HARTZLER A et al.: Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Neurochein. (2001) 79(2):311–318.
- D'AVERSA TG, WEIDENHEIM KM, BERMAN JW: CD4O-CD4OL interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus and multiple sclerosis. Am. Pathol. (2002) 160(2):559–567.
- WILMER WA, DIXON CL, HEBERT C: Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int. (2001) 60(3):858–871.
- PUIGSERVER P, RHEE J, LIN J: Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARy coactivator-1. Mol. Cell (2001) 8(5):971–982.
- MANDELKAR S, KONG AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis (2001) 6(6):469–477.
- SIMON C, SIMON M, VUCELIC G: The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp.Cell Res. (2001) 271(2):344–355.
- PURVES TA, MIDDLEMAS TA, AGTHONG S: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB (2001) 15(13):2508–2514.